SAN FRANCISCO, Jan 16 (Reuters) - More than half a dozen major drugmakers are participating in the Trump administration's speedier review program for new medicines, yet other leading pharmaceutical ...

Reviews of Sanofi’s diabetes drug Tzield and Disc Medicine’s blood-disorder medicine bitopertin stalled Tzield pushed back after adverse event reports; bitopertin delayed two weeks amid efficacy and ...

The Trump administration wants the public to weigh in as it prepares for a review of the federal subsistence program in Alaska, an action that the state’s largest Alaska Native group fears will weaken ...

Lizzy Lawrence leads STAT’s coverage of the Food and Drug Administration. She was previously a medical devices reporter. You can reach Lizzy on Signal at lizzylaw.53. WASHINGTON — A new program ...

This Comprehensive Review (CR), initiated by NAVAIR in September 2023, is based on the authority of Commander, Naval Air Systems Command, in ensuring the airworthiness of Naval aircraft. This covers ...

Abstract: Project and task scheduling under uncertainty remains a fundamental challenge in program and project management, where accurate estimation of task durations and dependencies is critical for ...

The FDA says it is hiring more than 1,000 new employees and rolling out a pilot communication program in an effort to speed up the review of new drugs. “FDA announced over 40 job announcements for ...

Two obesity drugs are among the six new medications that could get faster FDA review under a new pilot program open to products addressing certain national health priorities. Rare and infectious ...

The FDA is implementing a new pilot program that could incentivize development of certain new drugs by dramatically shortening their regulatory reviews. But to qualify, a drug must address specified ...

Quantifying patient preferences for bacillus Calmette-Guérin (BCG) and PD-(L)1 inhibitors in high-risk non-muscle invasive bladder cancer (NMIBC): A discrete choice experiment. This is an ASCO Meeting ...